Zynerba Pharmaceuticals (ZYNE) Reaches $10.05 After 6.00% Down Move; Kopernik Global Investors Upped Cameco (CCJ) Position By $6.53 Million

October 12, 2017 - By Michael Collier

The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! About 203,751 shares traded. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has risen 161.36% since October 12, 2016 and is uptrending. It has outperformed by 144.66% the S&P500.The move comes after 6 months negative chart setup for the $133.24 million company. It was reported on Oct, 12 by Barchart.com. We have $9.45 PT which if reached, will make NASDAQ:ZYNE worth $7.99 million less.

Kopernik Global Investors Llc increased Cameco Corp (CCJ) stake by 10.39% reported in 2017Q2 SEC filing. Kopernik Global Investors Llc acquired 725,037 shares as Cameco Corp (CCJ)’s stock declined 16.04%. The Kopernik Global Investors Llc holds 7.70 million shares with $70.11 million value, up from 6.98 million last quarter. Cameco Corp now has $3.56 billion valuation. The stock declined 0.44% or $0.04 reaching $9.09 on the news. About 754,083 shares traded. Cameco Corp (USA) (NYSE:CCJ) has declined 13.76% since October 12, 2016 and is downtrending. It has underperformed by 30.46% the S&P500.

Analysts await Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to report earnings on November, 13. They expect $-0.58 EPS, up 13.43% or $0.09 from last year’s $-0.67 per share. After $-0.64 actual EPS reported by Zynerba Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -9.38% EPS growth.

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has market cap of $133.24 million. The Firm is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. It currently has negative earnings. The Company’s development pipeline includes two product candidates: ZYN002 and ZYN001.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>